For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

By Amy Baxter • Feb. 23, 2024

Behind the breakthrough cancer therapy that just won a historic FDA nod

The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

By Kelly Bilodeau • Feb. 21, 2024

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

4 biotechs to watch in 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

By Alexandra Pecci • Feb. 21, 2024

Kite’s next-gen CAR-T aims include quicker production and more disease targets

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

By Kelly Bilodeau • Feb. 20, 2024

Value and potential of IoT and AI for chronic diseases treatment

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024

Pharma CFOs need R&D vigilance in tough economic times

Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

By Amy Baxter • Feb. 16, 2024

‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

Researchers are unleashing the powers of AI for precision medicine, drug development and more.

By Alexandra Pecci • Feb. 15, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

A new (old) mind-opening tool in the fight against Alzheimer’s disease

A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

By Kelly Bilodeau • Feb. 12, 2024

FDA inches closer to defining its regulatory role in AI

Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

By Amy Baxter • Feb. 12, 2024

Astellas’ science chief on the leap into new technologies

After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

By Meagan Parrish • Feb. 9, 2024

Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

By Michael Gibney • Feb. 8, 2024

Vaxxinity is brewing up meds for a spacefaring future

The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

By Kelly Bilodeau • Feb. 5, 2024

Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.  

By Michael Gibney • Jan. 31, 2024

Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

By Alexandra Pecci • Jan. 30, 2024

Tonix closes in on the first new fibromyalgia drug in more than a decade

In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

By Kelly Bilodeau • Jan. 29, 2024

‘1 plus 1 equals 3’ — the co-CEO model in pharma

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

By Meagan Parrish • Jan. 26, 2024

The biggest questions hanging over pharma in 2024

Key trends on the horizon in the life sciences this year.

By Meagan Parrish • Jan. 25, 2024

King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

By Michael Gibney • Jan. 25, 2024

Breast cancer tops list of most studied diseases

The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

By Kelly Bilodeau • Jan. 24, 2024

The hunt for an elusive universal coronavirus vaccine

A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

By Alexandra Pecci • Jan. 22, 2024

Controversial challenge trials offer unparalleled innovation — with ethical bumps

Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

By Kelly Bilodeau • Jan. 22, 2024

Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

By Meagan Parrish • Jan. 19, 2024

Pharma takes a gut check of microbiome drugs

On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

By Kelly Bilodeau • Jan. 16, 2024

Pharma execs sound off on trends and policies they’re tracking in 2024

From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

By Meagan Parrish • Jan. 12, 2024